A Study Comparing the Efficacy and Safety of Standard of Care With or Without Siltuximab in Selected Hospitalized Patients With Viral Acute Respiratory Distress Syndrome (SILVAR)
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Siltuximab (Primary) ; Dexamethasone; Dexamethasone
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Registrational; Therapeutic Use
- Acronyms SILVAR
- Sponsors EUSA Pharma
- 25 Feb 2021 Status changed from recruiting to suspended. (The REMAP-CAP and RECOVERY substudy results appear to support the survival benefit oftocilizumab in corticosteroid-treated or untreated patients with critically illCOVID-19-associated ARDS.)
- 17 Dec 2020 According to an EUSA Pharma media release, this study is designed to confirm the encouraging results of the observational SISCO study.
- 17 Dec 2020 According to an EUSA Pharma media release, the first patient has been enrolled in the study at the Sparrow Hospital in Lansing, Michigan.